Holen Sie sich die Stockscreener-App
0.46
6.08%
-0.0298
Schlusskurs vom Vortag:
$0.4898
Offen:
$0.4713
24-Stunden-Volumen:
769.40K
Relative Volume:
0.55
Marktkapitalisierung:
$16.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.73M
KGV:
-0.0319
EPS:
-14.3996
Netto-Cashflow:
$-13.18M
1W Leistung:
-6.06%
1M Leistung:
+5.41%
6M Leistung:
-37.18%
1J Leistung:
-78.80%
1-Tages-Spanne:
$0.44
$0.4829
1-Wochen-Bereich:
$0.44
$0.50
52-Wochen-Spanne:
$0.261
$2.31
Gt Biopharma Inc Stock (GTBP) Company Profile
Firmenname
Gt Biopharma Inc
Sektor
Branche
Telefon
(800) 304-9888
Adresse
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.49 | 2.97B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.01 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.20 | 349.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
4.72 | 358.07M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
47.37 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-02 | Eingeleitet | ROTH MKM | Buy |
| 2021-05-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-17 | Eingeleitet | ROTH Capital | Buy |
Gt Biopharma Inc Aktie (GTBP) Neueste Nachrichten
GT Biopharma (GTBP) Revenue BreakdownMain Composition - Moomoo
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs - The Globe and Mail
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (GTBP) plans reverse stock split and larger 2022 incentive plan - Stock Titan
Enterprise value to EBITDA forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Morningstar
Enterprise value to EBITDA forward of GT Biopharma Inc – MUN:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to book forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBITDA forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to revenue forward of GT Biopharma Inc – FWB:OXIA - TradingView
Enterprise value to EBIT forward of GT Biopharma, Inc. – NASDAQ:GTBP - TradingView
Price to sales forward of GT Biopharma Inc – FWB:OXIA - TradingView
Price to earnings forward of GT Biopharma Inc – FWB:OXIA - TradingView
GT Biopharma Inc Actuals & Estimates (SWB:OXIA) - TradingView
GT Biopharma Inc (GTBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OXIA Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc Actuals & Estimates (NASDAQ:GTBP) - TradingView
GTBP Forecast — Price Target — Prediction for 2027 - TradingView
GT Biopharma Inc (GTBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
GT Biopharma Inc (GTBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GTBP PE Ratio & Valuation, Is GTBP Overvalued - Intellectia AI
GT Biopharma Inc (GTBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GT Biopharma Stocklong-term cancer therapy strategy under review - AD HOC NEWS
GT Biopharma (NASDAQ: GTBP) proposes reverse split and 3.5M share plan increase - Stock Titan
GT Biopharma Inc (GTBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GT Biopharma Inc (GTBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GT Biopharma Inc (GTBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GT Biopharma Inc (GTBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GT Biopharma Inc (GTBP) Institutional Confidence - TradingKey
GTBP Q1 2026 Earnings: EPS Misses Estimates, Stock DeclinesPretax Income Report - Město Břeclav
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward EPS Estimate - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickOption Breadth - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
Finanzdaten der Gt Biopharma Inc-Aktie (GTBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):